Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug899 | Convalescent plasma Wiki | 1.00 |
drug4004 | placebo Wiki | 0.41 |
drug1592 | INO-4800 Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.29 |
D018352 | Coronavirus Infections NIH | 0.23 |
D007239 | Infection NIH | 0.17 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.
Description: Endpoint of the need for intubation or patient death in hospital
Measure: Intubation or death in hospital Time: Day 30Description: Endpoint of the need for intubation before 30 days
Measure: Need for Intubation Time: Day 30Description: Time in hours to intubation from randomization
Measure: Time to intubation Time: Day 30Description: Endpoint of the number of days off ventilator at 30 days
Measure: Ventilator-free days Time: Day 30Description: In-hospital death censored at 90 days
Measure: In-hospital death Time: 90 daysDescription: Time to in-hospital death at 90 days
Measure: Time to in-hospital death Time: Day 90Description: Death at 30 days
Measure: Death at 30 days Time: 30 daysDescription: Date of intensive care unit admission (first date and total number of days)
Measure: Length of stay in intensive care unit (ICU) Time: Day 30Description: Date of hospital admission (first date and total number of days)
Measure: Length of stay in hospital Time: Day 30Description: First date on ECMO and total number of days
Measure: Need for extracorpeal membrane oxygenation (ECMO) Time: Day 30Description: Need for renal replacement therapy
Measure: Need for renal replacement therapy Time: Day 30Description: New myocarditis
Measure: Development of myocarditis Time: Day 30Description: Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)
Measure: Adverse events and serious adverse events Time: Day 30Description: CCP transfusion-associated adverse events (AE)
Measure: CCP transfusion-associated adverse events (AE) Time: 30 daysThere is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. WCM is a U.S. sub-site to this pan-Canadian clinical trial (NCT04348656) which has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.
Description: Endpoint of the need for intubation or patient death in hospital
Measure: Intubation or death in hospital Time: Day 30Description: Endpoint of the need for intubation before 30 days
Measure: Need for Intubation Time: Day 30Description: Time in hours to intubation from randomization
Measure: Time to intubation Time: Day 30Description: Endpoint of the number of days off ventilator at 30 days
Measure: Ventilator-free days Time: Day 30Description: In-hospital death censored at 90 days
Measure: In-hospital death Time: 90 daysDescription: Time to in-hospital death at 90 days
Measure: Time to in-hospital death Time: Day 90Description: Death at 30 days
Measure: Death at 30 days Time: 30 daysDescription: Date of intensive care unit admission (first date and total number of days)
Measure: Length of stay in intensive care unit (ICU) Time: Day 30Description: Date of hospital admission (first date and total number of days)
Measure: Length of stay in hospital Time: Day 30Description: First date on ECMO and total number of days
Measure: Need for extracorpeal membrane oxygenation (ECMO) Time: Day 30Description: Need for renal replacement therapy
Measure: Need for renal replacement therapy Time: Day 30Description: New myocarditis
Measure: Development of myocarditis Time: Day 30Description: Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)
Measure: Adverse events and serious adverse events Time: Day 30Description: CCP transfusion-associated adverse events (AE)
Measure: CCP transfusion-associated adverse events (AE) Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports